Track topics on Twitter Track topics that are important to you
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving radiation therapy through a special catheter that is placed in the breast may kill any tumor cells that remain after surgery. It may also be an effective treatment for breast cancer.
PURPOSE: This phase II trial is studying how well internal radiation therapy works in treating women with early-stage breast cancer.
- To determine local disease control in women with early-stage breast cancer treated with shorter courses of accelerated partial-breast radiotherapy (APBI) delivered with a breast brachytherapy applicator.
- To determine whether the acceptable toxicity rates of APBI can be preserved when further accelerating the dose delivery scheme from the commonly applied ten treatments delivered twice daily over 5 days to two treatments delivered over 2 days.
- To assess the rate of excellent or good cosmesis at 3 years after shorter courses of APBI.
- To identify covariants associated with and predictive of poor cosmetic outcome in patients treated with an overnight course of APBI.
OUTLINE: This is a multicenter study.
Patients undergo placement of the Contura™ MLB device into the lumpectomy cavity followed by CT scan for treatment planning. Approximately 1-5 days after balloon placement, patients undergo accelerated partial-breast radiotherapy twice daily over 2 days.
After completion of study therapy, patients are followed up periodically for 5 years.
Allocation: Non-Randomized, Primary Purpose: Treatment
adjuvant therapy, accelerated partial breast irradiation, hypofractionated radiation therapy, intracavitary balloon brachytherapy
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
National Cancer Institute (NCI)
Published on BioPortfolio: 2014-08-27T03:17:44-0400
The investigators proposed approach allows them to deliver a low total dose of radiation to patients with low-risk, early-stage breast cancer which would further minimize the impact of adj...
This study is to evaluate the efficacy and toxicity of accelerated partial breast irradiation (ABPI) with intensity modulated radiation therapy (IMRT) in low-risk breast cancer treat with ...
This study is to compare radiation toxicity of accelerated partial breast irradiation (ABPI) with whole breast irradiation (WBI) in low-risk breast cancer.
This is a randomized phase III trial in women with invasive carcinoma of the breast with negative axillary nodes treated by Breast Conserving Surgery (BCS). Eligible, patients will be rand...
This phase II trial studies how well accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy works in treating patients with breast cancer that has not sprea...
Hypofractionated whole breast irradiation (HWBI) and accelerated partial breast irradiation (APBI) represent two adjuvant radiation therapy options following breast conserving surgery. We performed a ...
The Breast Cancer Group of the Japanese Radiation Oncology Study Group conducted a nationwide questionnaire survey on the clinical practice of postoperative radiotherapy for breast-conserving treatmen...
Hypofractionated whole-breast radiation therapy (RT) has proved to be equivalent to conventionally fractionated RT in multiple randomized trials. There is controversy regarding its use in younger wome...
To improve efficiency, convenience, and cost, a prospective phase II trial was initiated to evaluate accelerated partial breast irradiation delivered with noninvasive image-guided breast brachytherapy...
To prospectively characterize toxicity and cosmesis after accelerated partial breast irradiation (APBI) with 3D conformal radiotherapy (3D-CRT) or single-entry multilumen intracavitary brachytherapy.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
Irradiation of one half or both halves of the body in the treatment of disseminated cancer or widespread metastases. It is used to treat diffuse metastases in one session as opposed to multiple fields over an extended period. The more frequent treatment modalities are upper hemibody irradiation (UHBI) or lower hemibody irradiation (LHBI). Less common is mid-body irradiation (MBI). In the treatment of both halves of the body sequentially, hemibody irradiation permits radiotherapy of the whole body with larger doses of radiation than could be accomplished with WHOLE-BODY IRRADIATION. It is sometimes called "systemic" hemibody irradiation with reference to its use in widespread cancer or metastases. (P. Rubin et al. Cancer, Vol 55, p2210, 1985)
Radiation therapy used to treat the PITUITARY GLAND.
Abnormal accumulation of lymph in the arm, shoulder and breast area associated with surgical or radiation breast cancer treatments (e.g., MASTECTOMY).
Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
Track and monitor developments in breast cancer research and commercial development. Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...
Surgery is a technology consisting of a physical intervention on tissues. All forms of surgery are considered invasive procedures; so-called "noninvasive surgery" usually refers to an excision that does not penetrate the structure being exci...